SCHEMBL681498

SCHEMBL681498

CNCCc1ccc(OC)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.61
CHRM1 P11229 1/20 0.61
CHRM3 P20309 1/20 0.61
KDM4E B2RXH2 1/20 0.61
LMNA P02545 1/20 0.61
SMN1; SMN2 Q16637 3/20 0.59
ATM Q13315 2/20 0.58
POLB P06746 1/20 0.58
HTT P42858 1/20 0.58
MAPT P10636 1/20 0.58
CA12 O43570 1/20 0.58
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
CA5A P35218 1/20 0.58
CA9 Q16790 1/20 0.58
CA14 Q9ULX7 1/20 0.58
TAAR1 Q96RJ0 5/20 0.57
TMEM97 Q5BJF2 1/20 0.57
SIGMAR1 Q99720 1/20 0.57
ALDH1A1 P00352 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1029558 0.98 CHRM2 (0.59) CHRM2CHRM1CHRM3KDM4ELMNA
Formaldehyde SCHEMBL12492240 0.94 SMN1; SMN2 (0.59) CHRM2CHRM1CHRM3KDM4ELMNA
SCHEMBL4615272 0.88 CALM1 (0.58) KDM4ELMNASMN1; SMN2POLBHTT
Hydrochloric Acid SCHEMBL4615416 0.86 MEN1 (0.60) KDM4ELMNASMN1; SMN2POLBHTT
SCHEMBL28661867 0.84 SMN1; SMN2 (0.65) CHRM2KDM4ELMNASMN1; SMN2ATM
SCHEMBL13886531 0.84 SIGMAR1 (0.61) CHRM2KDM4ELMNASMN1; SMN2POLB
Trifluoroacetic Acid SCHEMBL5072989 0.83 SMN1; SMN2 (0.56) SMN1; SMN2ATMTAAR1ALDH1A1F2RL1
SCHEMBL10156581 0.83 TAAR1 (0.76) CHRM2CHRM1CHRM3KDM4ELMNA
SCHEMBL9667596 0.83 CHRM2 (0.67) CHRM2CHRM1CHRM3KDM4ELMNA
SCHEMBL17331156 0.83 TAAR1 (0.75) KDM4ELMNASMN1; SMN2HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 641 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260000678-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION TAKASAKI UNIV OF HEALTH AND WELFARE (JP) 2026-01-01 US claimed
EP-4583860-A1 INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2025-07-16 EP claimed
EP-4501357-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS Takasaki University of Health and Welfare (JP) 2025-02-05 EP claimed
CN-119233829-A Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy 学校法人高崎健康福祉大学 2024-12-31 CN claimed
CN-119143633-A Nitrobenzene-containing urea compound and preparation method and application thereof 西安交通大学 2024-12-17 CN claimed
CN-118599773-A Immune cell-based raw material screening model and screening of sensitive muscle raw materials by using same 广州市华代生物科技有限公司 2024-09-06 CN claimed
CN-118477091-A Lnc-MSTRG.32352.2 and application thereof 河北大学 2024-08-13 CN claimed
CN-118421747-A Combined method for evaluating in-vitro soothing efficacy of cosmetic raw materials 云南贝泰妮生物科技集团股份有限公司 2024-08-02 CN claimed
US-20240252610-A1 A BROADLY PROTECTIVE PROPHYLACTIC VACCINE AGAINST PSEUDOMONAS AERUGINOSA UNIVERSITY OF MARYLAND, BALTIMORE 2024-08-01 US claimed
EP-4340872-A2 A BROADLY PROTECTIVE PROPHYLACTIC VACCINE AGAINST PSEUDOMONAS AERUGINOSA University of Kansas (US) 2024-03-27 EP claimed
CN-114295535-A Method for rapidly detecting soothing effect of cosmetics through mast cell degranulation state 常州市艾斯康生物医药有限公司 2022-04-08 CN claimed
EP-2119363-B1 Enhanced antimicrobial activity of plant essential oils VAN BEEK RONALD R (US) 2019-01-09 EP claimed
EP-1501830-B1 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES ACTELION PHARMACEUTICALS LTD (CH) 2011-10-05 EP claimed
US-20080312242-A1 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES ACTELION PHARMACEUTICALS, LTD. (CH) 2008-12-18 US claimed
US-7427613-B2 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases ACTELION PHARMACEUTICALS LTD. (CH) 2008-09-23 US claimed
US-20050176700-A1 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases ACTELION PHARMACEUTICALS LTD. (CH) 2005-08-11 US claimed
EP-1501830-A1 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES Actelion Pharmaceuticals Ltd. (CH) 2005-02-02 EP claimed
WO-2003093267-A1 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES ACTELION PHARMACEUTICALS LTD (CH) 2003-11-13 WO claimed
EP-0308456-B1 COMPOSITON FOR THE TREATMENT OF THE EPIDERM SCHOEFF, Nadine (FR) 1991-12-04 EP claimed
US-4996057-A Human placental tissue proteins and a condensation product of n-methyl-p-methoxyphenethylamine with formaldehyde; hair growth Schoeff, Nadine (FR) 1991-02-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176700-A1 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases REN, AGTR1, ACE CHRM2 3509/4885CHRM1 2464/4885CHRM3 2273/4885
US-20260000678-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION TRPV1, TRPV4, TRPV5 CHRM2 790/4885CHRM1 533/4885CHRM3 286/4885
US-20080312242-A1 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES REN, AGTR1, ACE CHRM2 3509/4885CHRM1 2464/4885CHRM3 2273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.